{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:32:24Z","timestamp":1791995544289,"version":"4.4.0"},"reference-count":203,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:00:00Z","timestamp":1732060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Hypertension is a leading global risk factor for disability and death. Irbesartan, a potent angiotensin II receptor blocker, requires continuous safety monitoring. We conducted a disproportionality analysis of irbesartan-related adverse drug events (ADEs) using the FDA\u2019s FAERS and Japan\u2019s JADER databases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We extracted irbesartan-related ADE reports from FAERS (Q1 2004 to Q1 2024) and JADER (Q2 2008 to Q4 2023). We used Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Empirical Bayesian Geometric Mean (EBGM) for signal detection. Sensitivity analyses were conducted to exclude comorbid medications, and subgroup analyses by age and gender were performed to explore ADE occurrence in specific populations. Th time to onset (TTO) of ADEs was assessed using Weibull distribution test and Kaplan-Meier curves.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 5,816 (FAERS) and 366 (JADER) reports were analyzed, with irbesartan-related preferred terms (PTs) involving 27 System Organ Classes (SOCs) in FAERS and 22 in JADER. Three SOCs met detection thresholds in both databases: \u201cmetabolism and nutrition disorders,\u201d \u201ccardiac disorders,\u201d and \u201crenal and urinary disorders.\u201d We identified 219 positive signals in FAERS and 20 in JADER, including known signals like hyperkalemia, hypotension, and acute kidney injury. Notably, newly identified signals such as acute pancreatitis (n = 50, ROR: 7.76 [5.88\u201310.25]) and rhabdomyolysis (n = 50, ROR: 7.76 [5.88\u201310.25]) in FAERS and respiratory failure (n = 7, ROR: 6.76 [3.20\u201314.26]) in JADER could have significant clinical implications, as they may lead to severe outcomes if not recognized and managed promptly. Subgroup analyses revealed both similarities and differences in signal detection across gender and age groups. Sensitivity analyses, excluding concomitant medications, confirmed the persistence of key positive signals, including hyperkalemia, angioedema, acute pancreatitis, and agranulocytosis. ADEs mainly occurred within 1\u00a0month (34.14%) and after 1\u00a0year (32.32%) after dosing, with a median onset of 107\u00a0days.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study provides valuable real-world evidence on the safety profile of irbesartan. The identification of new safety signals underscores the necessity of updating drug labels, particularly for assessing and managing high-risk patients. Additionally, the TTO analysis emphasizes the importance of sustained vigilance for adverse events over time. In conclusion, our findings contribute to a more comprehensive understanding of irbesartan\u2019s safety, aiding healthcare professionals in optimizing its use in clinical practice.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1485190","type":"journal-article","created":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T04:33:51Z","timestamp":1732077231000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":32,"title":["A real-world pharmacovigilance analysis of adverse events associated with irbesartan using the FAERS and JADER databases"],"prefix":"10.3389","volume":"15","author":[{"given":"Qian","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1053\/j.ajkd.2006.07.006","article-title":"Anemia after renal transplantation","volume":"48","author":"Afzali","year":"2006","journal-title":"Am. J. Kidney Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"681","DOI":"10.3389\/fphar.2019.00681","article-title":"A new method for ethical and efficient evidence generation for off-label medication use in oncology (A case study in glioblastoma)","volume":"10","author":"Agrawal","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"n189","DOI":"10.1136\/bmj.n189","article-title":"Association between antihypertensive treatment and adverse events: systematic review and meta-analysis","volume":"372","author":"Albasri","year":"2021","journal-title":"BMJ"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1161\/CIRCRESAHA.116.307475","article-title":"Pharmacological strategies to retard cardiovascular aging","volume":"118","author":"Alfaras","year":"2016","journal-title":"Circ. Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/sj.clpt.6100258","article-title":"Novel statistical tools for monitoring the safety of marketed drugs","volume":"82","author":"Almenoff","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"16014","DOI":"10.3748\/wjg.v20.i43.16014","article-title":"Risk of infections associated with biological treatment in inflammatory bowel disease","volume":"20","author":"Andersen","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1097\/00042737-200208000-00014","article-title":"Cholestatic hepatitis related to use of irbesartan: a case report and a literature review of angiotensin II antagonist-associated hepatotoxicity","volume":"14","author":"Andrade","year":"2002","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1097\/00042737-200502000-00019","article-title":"Could irbesartan trigger autoimmune cholestatic hepatitis?","volume":"17","author":"Annicchiarico","year":"2005","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/1053-0770(93)90124-4","article-title":"Hyperkalemia and myocardial atonia following cardioselective beta-blockade","volume":"7","author":"Antrobus","year":"1993","journal-title":"J. Cardiothorac. Vasc. Anesth."},{"key":"B10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2165\/00002018-200932020-00004","article-title":"Treating hypertension in older adults: safety considerations","volume":"32","author":"Aronow","year":"2009","journal-title":"Drug Saf."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1038\/s41440-021-00731-0","article-title":"Productivity burden of hypertension in Japan","volume":"44","author":"Asakura","year":"2021","journal-title":"Hypertens. Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.cgh.2006.11.023","article-title":"Drug-induced acute pancreatitis: an evidence-based review","volume":"5","author":"Badalov","year":"2007","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1001\/jamasurg.2020.0089","article-title":"Colorectal cancer risk following bariatric surgery in a nationwide study of French individuals with obesity","volume":"155","author":"Bailly","year":"2020","journal-title":"JAMA Surg."},{"key":"B14","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1111\/j.1398-9995.2007.01427.x","article-title":"Nonallergic angioedema: role of bradykinin","volume":"62","author":"Bas","year":"2007","journal-title":"Allergy"},{"key":"B15","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1097\/00004836-200303000-00017","article-title":"Candesartan cilexetil-induced severe hepatotoxicity","volume":"36","author":"Basile","year":"2003","journal-title":"J. Clin. Gastroenterol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1038\/ki.2009.2","article-title":"Angiotensin II type 2 receptor deficiency aggravates renal injury and reduces survival in chronic kidney disease in mice","volume":"75","author":"Benndorf","year":"2009","journal-title":"Kidney Int."},{"key":"B18","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s40264-014-0196-1","article-title":"Drug-induced hyperkalemia","volume":"37","author":"Ben Salem","year":"2014","journal-title":"Drug Saf."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/s0140-6736(05)79122-4","article-title":"Pancreatitis after losartan","volume":"351","author":"Birck","year":"1998","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41569-018-0074-0","article-title":"Targeting mitochondria for cardiovascular disorders: therapeutic potential and obstacles","volume":"16","author":"Bonora","year":"2019","journal-title":"Nat. Rev. Cardiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2165\/11632100-000000000-00000","article-title":"The role of irbesartan in the treatment of patients with hypertension: a comprehensive and practical review","volume":"19","author":"Borghi","year":"2012","journal-title":"High. Blood Press Cardiovasc Prev."},{"key":"B22","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s10741-019-09869-z","article-title":"Hyperuricemia: a novel old disorder-relationship and potential mechanisms in heart failure","volume":"25","author":"Borghi","year":"2020","journal-title":"Heart Fail Rev."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1001\/jama.278.19.1572","article-title":"Losartan-induced hepatotoxicity","volume":"278","author":"Bosch","year":"","journal-title":"JAMA"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.7326\/0003-4819-127-11-199712010-00031","article-title":"Losartan-induced acute pancreatitis","volume":"127","author":"Bosch","year":"","journal-title":"Ann. Intern Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"447","DOI":"10.2165\/00003495-198427050-00004","article-title":"Effects of antihypertensive drugs on endocrine function","volume":"27","author":"Brass","year":"1984","journal-title":"Drugs"},{"key":"B26","doi-asserted-by":"publisher","first-page":"101015","DOI":"10.1016\/j.disamonth.2020.101015","article-title":"Rhabdomyolysis","volume":"66","author":"Cabral","year":"2020","journal-title":"Dis. Mon."},{"key":"B27","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3390\/ph16010057","article-title":"Association between use of spironolactone and risk of stroke in hypertensive patients: a cohort study","volume":"16","author":"Cai","year":"2022","journal-title":"Pharm. (Basel)"},{"key":"B28","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1161\/01.CIR.0000153269.07762.3B","article-title":"Losartan increases bradykinin levels in hypertensive humans","volume":"111","author":"Campbell","year":"2005","journal-title":"Circulation"},{"key":"B29","doi-asserted-by":"publisher","first-page":"001128","DOI":"10.12890\/2019_001128","article-title":"Late-onset rash from irbesartan: an immunological reaction","volume":"6","author":"Cardoso","year":"2019","journal-title":"Eur. J. Case Rep. Intern Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1001\/jama.2022.19590","article-title":"Treatment of hypertension: a review","volume":"328","author":"Carey","year":"2022","journal-title":"JAMA"},{"key":"B31","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s13054-016-1314-5","article-title":"Beyond muscle destruction: a systematic review of rhabdomyolysis for clinical practice","volume":"20","author":"Chavez","year":"2016","journal-title":"Crit. Care"},{"key":"B32","doi-asserted-by":"publisher","first-page":"8616194","DOI":"10.1155\/2018\/8616194","article-title":"Effects of irbesartan pretreatment on pancreatic \u03b2-cell apoptosis in STZ-induced acute prediabetic mice","volume":"2018","author":"Chen","year":"","journal-title":"Oxid. Med. Cell Longev."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e14428","DOI":"10.1097\/MD.0000000000014428","article-title":"Severe acute interstitial nephritis induced by valsartan: a case report","volume":"98","author":"Chen","year":"2019","journal-title":"Med. Baltim."},{"key":"B34","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.amjms.2018.01.017","article-title":"Effects of different doses of irbesartan combined with spironolactone on urinary albumin excretion rate in elderly patients with early type 2 diabetic nephropathy","volume":"355","author":"Chen","year":"","journal-title":"Am. J. Med. Sci."},{"key":"B35","doi-asserted-by":"publisher","first-page":"4572","DOI":"10.2174\/092986712803306411","article-title":"Mechanisms of fetal and neonatal renal impairment by pharmacologic inhibition of angiotensin","volume":"19","author":"Chevalier","year":"2012","journal-title":"Curr. Med. Chem."},{"key":"B36","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/hr.2015.82","article-title":"Impact of irbesartan, an angiotensin receptor blocker, on uric acid level and oxidative stress in high-risk hypertension patients","volume":"38","author":"Chida","year":"2015","journal-title":"Hypertens. Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/0006-291x(89)91054-1","article-title":"Identification of angiotensin II receptor subtypes","volume":"165","author":"Chiu","year":"1989","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B38","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/j.1365-2133.2006.07338.x","article-title":"Systemic illness with skin eruption, fever and positive lymphocyte transformation test in a patient on irbesartan","volume":"155","author":"Constable","year":"2006","journal-title":"Br. J. Dermatol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"599","DOI":"10.2165\/11599740-000000000-00000","article-title":"A signal detection method to detect adverse drug reactions using a parametric time-to-event model in simulated cohort data","volume":"35","author":"Cornelius","year":"2012","journal-title":"Drug Saf."},{"key":"B40","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.archger.2014.08.002","article-title":"Severe hyponatremia in older patients at admission in an internal medicine department","volume":"59","author":"Correia","year":"2014","journal-title":"Arch. Gerontol. Geriatr."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1259908","DOI":"10.3389\/fphar.2023.1259908","article-title":"A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?","volume":"14","author":"Cui","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/s0006-3223(98)00043-2","article-title":"Multiple correlations and Bonferroni's correction","volume":"44","author":"Curtin","year":"1998","journal-title":"Biol. Psychiatry"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1002\/ejhf.609","article-title":"Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme","volume":"18","author":"Damman","year":"2016","journal-title":"Eur. J. Heart Fail"},{"key":"B44","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/sj.jhh.1001941","article-title":"Effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia in Chinese population","volume":"20","author":"Dang","year":"2006","journal-title":"J. Hum. Hypertens."},{"key":"B45","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.ahj.2006.05.030","article-title":"Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction: a retrospective analysis of the Studies of Left Ventricular Dysfunction (SOLVD) trials","volume":"152","author":"de Denus","year":"2006","journal-title":"Am. Heart J."},{"key":"B46","doi-asserted-by":"publisher","first-page":"S224","DOI":"10.1097\/01.asn.0000032544.37147.ae","article-title":"Renal and cardiovascular protection in type 2 diabetes mellitus: angiotensin II receptor blockers","volume":"13","author":"Deferrari","year":"2002","journal-title":"J. Am. Soc. Nephrol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"120","DOI":"10.2174\/157016109787455644","article-title":"Irbesartan and hydrochlorothiazide association in the treatment of hypertension","volume":"7","author":"Derosa","year":"2009","journal-title":"Curr. Vasc. Pharmacol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1016\/j.jacc.2007.07.067","article-title":"Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program","volume":"50","author":"Desai","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1081\/jdi-100101967","article-title":"End-stage renal failure after irbesartan prescription in a diabetic patient with previously stable chronic renal insufficiency","volume":"22","author":"Descombes","year":"2000","journal-title":"Ren. Fail"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1056\/NEJMoa0805710","article-title":"Valsartan for prevention of recurrent atrial fibrillation","volume":"360","author":"Disertori","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2165\/00002018-199410020-00001","article-title":"Harmonisation in pharmacovigilance","volume":"10","author":"Edwards","year":"1994","journal-title":"Drug Saf."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1080\/00365520600761676","article-title":"Antihypertensive medication and the risk of acute pancreatitis: the European case-control study on drug-induced acute pancreatitis (EDIP)","volume":"41","author":"Eland","year":"2006","journal-title":"Scand. J. Gastroenterol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/nature742","article-title":"Molecular identification of a renal urate anion exchanger that regulates blood urate levels","volume":"417","author":"Enomoto","year":"2002","journal-title":"Nature"},{"key":"B54","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1016\/j.transproceed.2005.03.085","article-title":"Anemia due to losartan in hypertensive renal transplant recipients without posttransplant erythrocytosis","volume":"37","author":"Ersoy","year":"2005","journal-title":"Transpl. Proc."},{"key":"B55","doi-asserted-by":"publisher","first-page":"00553","DOI":"10.1016\/j.medcli.2024.07.021","article-title":"Drug-induced hyponatraemia and possible related signals: analysis of 659 cases reported to the Spanish Pharmacovigilance System and disproportionality analysis","author":"Est\u00e9vez Asensio","year":"2024","journal-title":"Med. Clin. Barc."},{"key":"B56","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1016\/j.neurobiolaging.2011.05.005","article-title":"Body mass index is associated with biological CSF markers of core brain pathology of Alzheimer's disease","volume":"33","author":"Ewers","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"B58","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1097\/01.mpa.0000178281.58158.64","article-title":"Acute pancreatitis associated with irbesartan therapy","volume":"31","author":"Famularo","year":"2005","journal-title":"Pancreas"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1425171","DOI":"10.3389\/fphar.2024.1425171","article-title":"Neratinib safety evaluation: real-world adverse event analysis from the FAERS database","volume":"15","author":"Fan","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1345\/aph.1C099","article-title":"Acute pancreatitis associated with angiotensin II receptor antagonists","volume":"36","author":"Fisher","year":"2002","journal-title":"Ann. Pharmacother."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1097\/00004872-199715120-00020","article-title":"24-hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring. Irbesartan Multicenter Investigators' Group","volume":"15","author":"Fogari","year":"1997","journal-title":"J. Hypertens."},{"key":"B62","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/dth.12063","article-title":"Frictional purpuric eruption associated with angiotensin II receptor blockers","volume":"27","author":"Foti","year":"2014","journal-title":"Dermatol Ther."},{"key":"B63","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1177\/0897190019828915","article-title":"Sacubitril\/valsartan (Entresto\u00ae)-Induced hyponatremia","volume":"33","author":"Fuzaylova","year":"2020","journal-title":"J. Pharm. Pract."},{"key":"B64","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1046\/j.1468-3083.2003.00614_3.x","article-title":"Exanthematous reaction to irbesartan","volume":"17","author":"Gambini","year":"2003","journal-title":"J. Eur. Acad. Dermatol Venereol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.farma.2011.05.005","article-title":"Leukoneutropenia associated with irbesartan","volume":"36","author":"G\u00f3mez-Sayago","year":"2012","journal-title":"Farm Hosp."},{"key":"B66","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s002280000220","article-title":"Candesartan and acute liver injury","volume":"56","author":"Gonz\u00e1lez-Jim\u00e9nez","year":"2000","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1038\/ki.2009.59","article-title":"Angiotensin II type 2 receptor in chronic kidney disease: the good side of angiotensin II?","volume":"75","author":"Griffin","year":"2009","journal-title":"Kidney Int."},{"key":"B68","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/fcp.12741","article-title":"Diarrhea and angiotensin II receptor blockers: is there any difference between the different drugs?","volume":"36","author":"Guion-Firmin","year":"2022","journal-title":"Fundam. Clin. Pharmacol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.sapharm.2005.06.005","article-title":"Comparison of potentially hepatotoxic drugs among major US drug compendia","volume":"1","author":"Guo","year":"2005","journal-title":"Res. Soc. Adm. Pharm."},{"key":"B70","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1136\/bmj.321.7260.547","article-title":"Drug points: prolonged cholestasis associated with irbesartan","volume":"321","author":"Hariraj","year":"2000","journal-title":"BMJ"},{"key":"B71","doi-asserted-by":"publisher","first-page":"310","DOI":"10.5414\/CP203237","article-title":"Risk factors for rhabdomyolysis with HMG-CoA reductase inhibitors identified using a postmarketing surveillance database in Japan","volume":"56","author":"Hashiguchi","year":"2018","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"B72","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/sj.bjp.0704462","article-title":"Blockade of bradykinin B(2) receptor suppresses acute pancreatitis induced by obstruction of the pancreaticobiliary duct in rats","volume":"135","author":"Hirata","year":"2002","journal-title":"Br. J. Pharmacol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/s41371-021-00534-3","article-title":"Epidemiology and control of hypertension in Japan: a comparison with Western countries","volume":"38","author":"Hisamatsu","year":"2024","journal-title":"J. Hum. Hypertens."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/s41440-020-0508-z","article-title":"Epidemiology of hypertension in Japan: beyond the new 2019 Japanese guidelines","volume":"43","author":"Hisamatsu","year":"2020","journal-title":"Hypertens. Res."},{"key":"B75","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.coph.2012.04.002","article-title":"Drug induced rhabdomyolysis","volume":"12","author":"Hohenegger","year":"2012","journal-title":"Curr. Opin. Pharmacol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1213\/ANE.0000000000002837","article-title":"A systematic review of outcomes associated with withholding or continuing angiotensin-converting enzyme inhibitors and angiotensin receptor blockers before noncardiac surgery","volume":"127","author":"Hollmann","year":"2018","journal-title":"Anesth. Analg."},{"key":"B77","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2165\/00002018-200225020-00001","article-title":"Can angiotensin receptor antagonists be used safely in patients with previous ACE inhibitor-induced angioedema?","volume":"25","author":"Howes","year":"2002","journal-title":"Drug Saf."},{"key":"B78","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1159\/000477946","article-title":"Renoprotective effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in diabetic patients with proteinuria","volume":"42","author":"Hsu","year":"2017","journal-title":"Kidney Blood Press Res."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1161\/CIRCULATIONAHA.115.018622","article-title":"Combined angiotensin receptor antagonism and neprilysin inhibition","volume":"133","author":"Hubers","year":"2016","journal-title":"Circulation"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1253\/circj.CJ-16-0283","article-title":"Coexisting hyponatremia and decline in diastolic blood pressure predispose to atrial standstill in hyperkalemic patients","volume":"80","author":"Ideguchi","year":"2016","journal-title":"Circ. J."},{"key":"B81","doi-asserted-by":"publisher","first-page":"633","DOI":"10.2147\/DDDT.S191973","article-title":"Efficacy of a fixed dose combination of irbesartan and atorvastatin (Rovelito\u00ae) in Korean adults with hypertension and hypercholesterolemia","volume":"13","author":"Ihm","year":"2019","journal-title":"Drug Des. Devel Ther."},{"key":"B82","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1038\/s41598-022-06611-y","article-title":"Preventive effect of rebamipide on NSAID-induced lower gastrointestinal tract injury using FAERS and JADER","volume":"12","author":"Imai","year":"2022","journal-title":"Sci. Rep."},{"key":"B83","doi-asserted-by":"publisher","first-page":"874","DOI":"10.3389\/fphar.2019.00874","article-title":"Risk evaluation for acute kidney injury induced by the concomitant use of valacyclovir, analgesics, and renin-angiotensin system inhibitors: the detection of signals of drug-drug interactions","volume":"10","author":"Inaba","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1124\/jpet.106.112755","article-title":"Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter","volume":"320","author":"Iwanaga","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B85","doi-asserted-by":"publisher","first-page":"5317","DOI":"10.1111\/bcp.15460","article-title":"Adverse event profiles of PCSK9 inhibitors alirocumab and evolocumab: data mining of the FDA adverse event reporting system","volume":"88","author":"Ji","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1186\/s12888-024-05813-0","article-title":"Exploring adverse events of Vilazodone: evidence from the FAERS database","volume":"24","author":"Jiang","year":"2024","journal-title":"BMC Psychiatry"},{"key":"B87","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/s0895-7061(97)00491-3","article-title":"Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan\/Losartan Study Investigators","volume":"11","author":"Kassler-Taub","year":"1998","journal-title":"Am. J. Hypertens."},{"key":"B88","doi-asserted-by":"publisher","first-page":"803706","DOI":"10.3389\/fphar.2022.803706","article-title":"Frequency of immune checkpoint inhibitor-induced vasculitides: an observational study using data from the Japanese adverse drug event report database","volume":"13","author":"Kato","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"H2516","DOI":"10.1152\/ajpheart.00424.2007","article-title":"Angiotensin II attenuates myocardial interstitial acetylcholine release in response to vagal stimulation","volume":"293","author":"Kawada","year":"2007","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1291\/hypres.31.1753","article-title":"A randomized trial of the effect of an angiotensin II receptor blocker SR47436 (irbesartan) on 24-hour blood pressure in patients with essential hypertension","volume":"31","author":"Kawano","year":"2008","journal-title":"Hypertens. Res."},{"key":"B91","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3390\/jcdd8070080","article-title":"Effects of statins on renin-angiotensin system","volume":"8","author":"Kiaie","year":"2021","journal-title":"J. Cardiovasc Dev. Dis."},{"key":"B92","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/jcpt.13024","article-title":"Time-to-onset analysis of amiodarone-associated thyroid dysfunction","volume":"45","author":"Kinoshita","year":"2020","journal-title":"J. Clin. Pharm. Ther."},{"key":"B93","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1161\/HYPERTENSIONAHA.113.00543","article-title":"Prevention of hypertension and cardiovascular diseases: a comparison of lifestyle factors in Westerners and East Asians","volume":"63","author":"Kokubo","year":"2014","journal-title":"Hypertension"},{"key":"B94","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1016\/S0140-6736(09)61913-9","article-title":"Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial","volume":"374","author":"Konstam","year":"2009","journal-title":"Lancet"},{"key":"B95","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1691\/ph.2023.2584","article-title":"Adverse drug event profile associated with anti-dementia drugs: analysis of a spontaneous reporting database","volume":"78","author":"Kose","year":"2023","journal-title":"Pharmazie"},{"key":"B96","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/s0002-8703(96)90365-8","article-title":"Adverse effects of enalapril in the studies of left ventricular dysfunction (SOLVD). SOLVD investigators","volume":"131","author":"Kostis","year":"1996","journal-title":"Am. Heart J."},{"key":"B97","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/nrneph.2014.168","article-title":"Management of hyperkalaemia in chronic kidney disease","volume":"10","author":"Kovesdy","year":"2014","journal-title":"Nat. Rev. Nephrol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/s0149-2918(00)83064-7","article-title":"A multicenter, randomized, double-blind study of the antihypertensive efficacy and tolerability of irbesartan in patients aged > or = 65 years with mild to moderate hypertension","volume":"22","author":"Lacourci\u00e8re","year":"2000","journal-title":"Clin. Ther."},{"key":"B99","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1016\/s0002-9149(97)00784-4","article-title":"Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension. Irbesartan Multicenter Investigators","volume":"80","author":"Larochelle","year":"1997","journal-title":"Am. J. Cardiol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/s0002-9343(01)00784-7","article-title":"Acute oliguric renal failure associated with angiotensin II receptor antagonists","volume":"111","author":"Lee","year":"2001","journal-title":"Am. J. Med."},{"key":"B101","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1056\/NEJMra021844","article-title":"Drug-induced hepatotoxicity","volume":"349","author":"Lee","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"B102","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1471-2288-14-17","article-title":"Estimating time-to-onset of adverse drug reactions from spontaneous reporting databases","volume":"14","author":"Leroy","year":"2014","journal-title":"BMC Med. Res. Methodol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"B104","doi-asserted-by":"publisher","first-page":"1358592","DOI":"10.3389\/fphar.2024.1358592","article-title":"Analysis of adverse drug reactions of Denosumab (Prolia) in osteoporosis based on FDA adverse event reporting system (FAERS)","volume":"15","author":"Li","year":"","journal-title":"Front. Pharmacol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s40360-024-00790-2","article-title":"Safety assessment of Tafamidis: a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events","volume":"25","author":"Li","year":"","journal-title":"BMC Pharmacol. Toxicol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1053\/j.ajkd.2008.03.004","article-title":"A review of drug-induced hyponatremia","volume":"52","author":"Liamis","year":"2008","journal-title":"Am. J. Kidney Dis."},{"key":"B107","doi-asserted-by":"publisher","first-page":"1420478","DOI":"10.3389\/fphar.2024.1420478","article-title":"Safety of tildrakizumab: a disproportionality analysis based on the FDA adverse event reporting system (FAERS) database from 2018-2023","volume":"15","author":"Lin","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41586-023-06680-7","article-title":"Vagal sensory neurons mediate the Bezold-Jarisch reflex and induce syncope","volume":"623","author":"Lovelace","year":"2023","journal-title":"Nature"},{"key":"B109","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","article-title":"Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies","volume":"77","author":"Luna","year":"2020","journal-title":"JAMA Neurol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"CD003235","DOI":"10.1002\/14651858.CD003235.pub2","article-title":"Emergency interventions for hyperkalaemia","volume":"2005","author":"Mahoney","year":"2005","journal-title":"Cochrane Database Syst. Rev."},{"key":"B111","doi-asserted-by":"publisher","first-page":"417","DOI":"10.2165\/11532850-000000000-00000","article-title":"Modelling the time to onset of adverse reactions with parametric survival distributions: a potential approach to signal detection and evaluation","volume":"33","author":"Maignen","year":"2010","journal-title":"Drug Saf."},{"key":"B112","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3390\/ijms18010106","article-title":"The diagnostic usefulness of serum total bile acid concentrations in the early phase of acute pancreatitis of varied etiologies","volume":"18","author":"Maleszka","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"B113","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1161\/CIRCRESAHA.116.308963","article-title":"Trends in NHLBI-funded research on sex differences in hypertension","volume":"119","author":"Maric-Bilkan","year":"2016","journal-title":"Circ. Res."},{"key":"B115","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1053\/j.gastro.2018.11.081","article-title":"Genetics, cell biology, and pathophysiology of pancreatitis","volume":"156","author":"Mayerle","year":"2019","journal-title":"Gastroenterology"},{"key":"B116","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1080\/14712598.2021.1948529","article-title":"The impact of anti-TNF\u03b1 agents on weight-related changes: new insights from a real-world pharmacovigilance study using the FDA adverse event reporting system (FAERS) database","volume":"21","author":"Mazhar","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"B117","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1161\/01.hyp.33.3.850","article-title":"Angiotensin II receptor blockade in normotensive subjects: a direct comparison of three AT1 receptor antagonists","volume":"33","author":"Mazzolai","year":"1999","journal-title":"Hypertension"},{"key":"B119","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.jacc.2014.04.080","article-title":"Renin-Angiotensin system blockade and worsening renal function in heart failure: an unfinished story","volume":"64","author":"Metra","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"B120","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s00125-010-1922-6","article-title":"Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial","volume":"54","author":"Miao","year":"2011","journal-title":"Diabetologia"},{"key":"B122","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1136\/postgradmedj-2020-139284","article-title":"Chronic asymptomatic hyponatraemia following angiotensin receptor blocker-neprilysin inhibitor (ARNi) therapy: a case report","volume":"98","author":"Mohammed","year":"2022","journal-title":"Postgrad. Med. J."},{"key":"B124","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/s0149-2918(04)90022-7","article-title":"The KARTAN study: a postmarketing assessment of Irbesartan in patients with hypertension","volume":"26","author":"Morales-Olivas","year":"2004","journal-title":"Clin. Ther."},{"key":"B125","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1161\/CIR.0000000000000152","article-title":"Heart disease and stroke statistics--2015 update: a report from the American Heart Association","volume":"131","author":"Mozaffarian","year":"2015","journal-title":"Circulation"},{"key":"B126","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/hr.2015.94","article-title":"Secular trends of the impact of overweight and obesity on hypertension in Japan, 1980-2010","volume":"38","author":"Nagai","year":"2015","journal-title":"Hypertens. Res."},{"key":"B127","doi-asserted-by":"publisher","first-page":"572","DOI":"10.3109\/10641960902929420","article-title":"Safety and tolerability of fixed-dose irbesartan\/hydrochlorothiazide for rapid control of severe hypertension","volume":"31","author":"Neutel","year":"2009","journal-title":"Clin. Exp. Hypertens."},{"key":"B128","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1111\/j.1365-2796.2005.01547.x","article-title":"Hypotensive shock and angio-oedema from angiotensin II receptor blocker: a class effect in spite of tripled tryptase values","volume":"258","author":"Nielsen","year":"2005","journal-title":"J. Intern Med."},{"key":"B129","doi-asserted-by":"publisher","first-page":"bbab347","DOI":"10.1093\/bib\/bbab347","article-title":"Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source","volume":"22","author":"Noguchi","year":"2021","journal-title":"Brief. Bioinform"},{"key":"B130","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.2147\/DDDT.S81998","article-title":"Effect of database profile variation on drug safety assessment: an analysis of spontaneous adverse event reports of Japanese cases","volume":"9","author":"Nomura","year":"2015","journal-title":"Drug Des. Devel Ther."},{"key":"B131","doi-asserted-by":"publisher","first-page":"x21","DOI":"10.1093\/annonc\/mdz440","article-title":"Management of toxicity to isoform \u03b1-specific PI3K inhibitors","volume":"30","author":"Nunnery","year":"2019","journal-title":"Ann. Oncol."},{"key":"B132","doi-asserted-by":"publisher","first-page":"23247096211037463","DOI":"10.1177\/23247096211037463","article-title":"Sprue-like enteropathy and liver injury: a rare emerging association with olmesartan","volume":"9","author":"Odak","year":"2021","journal-title":"J. Investig. Med. High. Impact Case Rep."},{"key":"B133","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/cam4.1920","article-title":"Pharmacovigilance evaluation of the relationship between impaired glucose metabolism and BCR-ABL inhibitor use by using an adverse drug event reporting database","volume":"8","author":"Okada","year":"2019","journal-title":"Cancer Med."},{"key":"B135","doi-asserted-by":"publisher","first-page":"e12748","DOI":"10.1111\/dth.12748","article-title":"Angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers induced pemphigus: a case series and literature review","volume":"32","author":"Palleria","year":"2019","journal-title":"Dermatol Ther."},{"key":"B136","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1093\/ndt\/gfg282","article-title":"Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what to do if the serum creatinine and\/or serum potassium concentration rises","volume":"18","author":"Palmer","year":"2003","journal-title":"Nephrol. Dial. Transpl."},{"key":"B137","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJMra035279","article-title":"Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system","volume":"351","author":"Palmer","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"B138","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/BF03261834","article-title":"Comparison of hyperkalemic risk in hospitalized patients treated with different angiotensin receptor blockers: a retrospective cohort study using a Korean clinical research database","volume":"12","author":"Park","year":"2012","journal-title":"Am. J. Cardiovasc Drugs"},{"key":"B139","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"B140","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41569-019-0244-8","article-title":"Counter-regulatory renin-angiotensin system in cardiovascular disease","volume":"17","author":"Paz Ocaranza","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"B141","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/ki.2014.69","article-title":"No significant effect of angiotensin II receptor blockade on intermediate cardiovascular end points in hemodialysis patients","volume":"86","author":"Peters","year":"2014","journal-title":"Kidney Int."},{"key":"B142","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1111\/j.1398-9995.2006.01052.x","article-title":"Lichenoid drug eruption due to an antihypertonic drug containing irbesartan and hydrochlorothiazide","volume":"61","author":"Pfab","year":"2006","journal-title":"Allergy"},{"key":"B143","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.emc.2023.07.005","article-title":"Disorders of potassium","volume":"41","author":"Piner","year":"2023","journal-title":"Emerg. Med. Clin. North Am."},{"key":"B144","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1476-5381.1982.tb08752.x","article-title":"Angiotensin inhibits action of vagus nerve at the heart","volume":"75","author":"Potter","year":"1982","journal-title":"Br. J. Pharmacol."},{"key":"B145","doi-asserted-by":"publisher","first-page":"e156","DOI":"10.1111\/j.1755-5922.2010.00258.x","article-title":"Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers","volume":"30","author":"Raebel","year":"2012","journal-title":"Cardiovasc Ther."},{"key":"B146","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/j.1365-2710.2005.00638.x","article-title":"Clinical factors associated with hyperkalemia in patients with congestive heart failure","volume":"30","author":"Ramadan","year":"2005","journal-title":"J. Clin. Pharm. Ther."},{"key":"B147","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.jacc.2015.06.1084","article-title":"Orthostatic hypotension: epidemiology, prognosis, and treatment","volume":"66","author":"Ricci","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"B148","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1177\/1074248413501018","article-title":"Renin-angiotensin system blocking drugs","volume":"19","author":"Robles","year":"2014","journal-title":"J. Cardiovasc Pharmacol. Ther."},{"key":"B149","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/nrneph.2012.217","article-title":"Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy","volume":"8","author":"Roscioni","year":"2012","journal-title":"Nat. Rev. Nephrol."},{"key":"B150","doi-asserted-by":"publisher","first-page":"310","DOI":"10.6002\/ect.2013.0172","article-title":"Acidosis and hyperkalemia caused by losartan and enalapril in pediatric kidney transplant recipients","volume":"12","author":"Sakall\u0131","year":"2014","journal-title":"Exp. Clin. Transpl."},{"key":"B151","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s40264-013-0061-7","article-title":"Illustration of the weibull shape parameter signal detection tool using electronic healthcare record data","volume":"36","author":"Sauzet","year":"2013","journal-title":"Drug Saf."},{"key":"B152","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/s0140-6736(05)60259-0","article-title":"Anaemia in dialysis patients as a side-effect of sartanes","volume":"352","author":"Schwarzbeck","year":"1998","journal-title":"Lancet"},{"key":"B153","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/sj.jhh.1001765","article-title":"Prevalence of hypertension, its awareness and control in adult population in Japan","volume":"18","author":"Sekikawa","year":"2004","journal-title":"J. Hum. Hypertens."},{"key":"B154","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/sj.jhh.1001190","article-title":"Angiotensin receptor antagonists and vaso-vagal attacks due to sensitisation of the Bezold-Jarisch reflex?","volume":"15","author":"Sever","year":"2001","journal-title":"J. Hum. Hypertens."},{"key":"B155","doi-asserted-by":"publisher","first-page":"15774","DOI":"10.1038\/s41598-024-64867-y","article-title":"Retrospective analysis of neoplasms in patients using angiotensin receptor blockers","volume":"14","author":"Sharma","year":"2024","journal-title":"Sci. Rep."},{"key":"B156","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s13300-019-0611-9","article-title":"A survey of the FDA's adverse event reporting system database concerning urogenital tract infections and sodium glucose cotransporter-2 inhibitor use","volume":"10","author":"Shen","year":"2019","journal-title":"Diabetes Ther."},{"key":"B157","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1210\/endo-125-1-486","article-title":"Production of renin, angiotensin II, and aldosterone by adrenal explant cultures: response to potassium and converting enzyme inhibition","volume":"125","author":"Shier","year":"1989","journal-title":"Endocrinology"},{"key":"B158","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1536\/ihj.16-285","article-title":"Comparison of efficacy and safety of azilsartan and olmesartan in patients with essential hypertension","volume":"58","author":"Shiga","year":"2017","journal-title":"Int. Heart J."},{"key":"B159","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/s0002-9149(98)00313-0","article-title":"Safety of irbesartan in the treatment of mild to moderate systemic hypertension","volume":"82","author":"Simon","year":"1998","journal-title":"Am. J. Cardiol."},{"key":"B160","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1007\/s00467-006-0400-3","article-title":"Severe anemia caused by the angiotensin receptor blocker irbesartan after renal transplantation","volume":"22","author":"Simonetti","year":"2007","journal-title":"Pediatr. Nephrol."},{"key":"B161","doi-asserted-by":"publisher","first-page":"185","DOI":"10.4103\/0976-500X.162004","article-title":"International conference on harmonization of technical requirements for registration of pharmaceuticals for human use","volume":"6","author":"Singh","year":"2015","journal-title":"J. Pharmacol. Pharmacother."},{"key":"B162","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1097\/HJH.0b013e32835200f9","article-title":"An initial reduction in serum uric acid during angiotensin receptor blocker treatment is associated with cardiovascular protection: a post-hoc analysis of the RENAAL and IDNT trials","volume":"30","author":"Smink","year":"2012","journal-title":"J. Hypertens."},{"key":"B163","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.2147\/DDDT.S466904","article-title":"Effectiveness of spironolactone in reducing osteoporosis and future fracture risk in middle-aged and elderly hypertensive patients","volume":"18","author":"Song","year":"2024","journal-title":"Drug Des. Devel Ther."},{"key":"B164","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14740338.2024.2393279","article-title":"A pharmacovigilance study assessing risk of angioedema with angiotensin receptor blockers using the US FDA Adverse Event Reporting System","author":"Sridharan","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"key":"B165","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1080\/000155501317140007","article-title":"Angiotensin-converting enzyme inhibitors as inducers of adverse cutaneous reactions","volume":"81","author":"Steckelings","year":"2001","journal-title":"Acta Derm. Venereol."},{"key":"B166","first-page":"143","article-title":"The healthcare cost and utilization project: an overview","volume":"5","author":"Steiner","year":"2002","journal-title":"Eff. Clin. Pract."},{"key":"B167","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/080370598437547","article-title":"Comparison of the angiotensin II receptor antagonist irbesartan with atenolol for treatment of hypertension","volume":"7","author":"Stumpe","year":"1998","journal-title":"Blood Press"},{"key":"B168","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.amjcard.2021.11.026","article-title":"Potential safety signals for rhabdomyolysis associated with high-potency statin use with or without sacubitril\/valsartan","volume":"166","author":"Sunaga","year":"2022","journal-title":"Am. J. Cardiol."},{"key":"B169","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","article-title":"Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database","volume":"25","author":"Szarfman","year":"2002","journal-title":"Drug Saf."},{"key":"B170","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.2169\/internalmedicine.2059-18","article-title":"Duloxetine and angiotensin II receptor blocker combination potentially induce severe hyponatremia in an elderly woman","volume":"58","author":"Takayama","year":"2019","journal-title":"Intern Med."},{"key":"B171","doi-asserted-by":"publisher","first-page":"5052","DOI":"10.1038\/s41467-018-07345-0","article-title":"Interethnic analyses of blood pressure loci in populations of East Asian and European descent","volume":"9","author":"Takeuchi","year":"2018","journal-title":"Nat. Commun."},{"key":"B172","doi-asserted-by":"publisher","first-page":"513","DOI":"10.7326\/0003-4819-115-7-513","article-title":"Reversible renal insufficiency due to angiotensin converting enzyme inhibitors in hypertensive nephrosclerosis","volume":"115","author":"Toto","year":"1991","journal-title":"Ann. Intern Med."},{"key":"B173","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.3748\/wjg.v18.i18.2270","article-title":"Role of bone marrow-derived mesenchymal stem cells in a rat model of severe acute pancreatitis","volume":"18","author":"Tu","year":"2012","journal-title":"World J. Gastroenterol."},{"key":"B174","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/s0025-7753(00)71672-1","article-title":"Acute hepatitis induced by candesartan","volume":"115","author":"Vallejo","year":"2000","journal-title":"Med. Clin. Barc."},{"key":"B175","doi-asserted-by":"publisher","first-page":"4809","DOI":"10.1038\/s41467-020-18396-7","article-title":"Transcriptomic profiling of human cardiac cells predicts protein kinase inhibitor-associated cardiotoxicity","volume":"11","author":"van Hasselt","year":"2020","journal-title":"Nat. Commun."},{"key":"B176","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B177","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1093\/ndt\/13.8.1928","article-title":"The acute renal effects of angiotensin II receptor blockers","volume":"13","author":"Veelken","year":"1998","journal-title":"Nephrol. Dial. Transpl."},{"key":"B178","doi-asserted-by":"publisher","first-page":"447","DOI":"10.3109\/08923973.2013.797992","article-title":"Eczematous reactions due to angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers","volume":"35","author":"Vena","year":"2013","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"B179","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.amjmed.2013.07.006","article-title":"Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations","volume":"126","author":"Verbalis","year":"2013","journal-title":"Am. J. Med."},{"key":"B180","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s40264-015-0323-7","article-title":"Photosensitivity with angiotensin II receptor blockers: a retrospective study using data from VigiBase(\u00ae)","volume":"38","author":"Viola","year":"2015","journal-title":"Drug Saf."},{"key":"B181","doi-asserted-by":"publisher","first-page":"995522","DOI":"10.3389\/fphar.2022.995522","article-title":"Data mining and safety analysis of BTK inhibitors: a pharmacovigilance investigation based on the FAERS database","volume":"13","author":"Wan","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B183","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1016\/j.ekir.2024.07.006","article-title":"Exploring novel adverse events of nefecon","volume":"9","author":"Wang","year":"2024","journal-title":"Kidney Int. Rep."},{"key":"B184","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.jad.2024.07.034","article-title":"Clinical safety of daridorexant in insomnia treatment: analysis of FDA adverse event reports","volume":"362","author":"Wang","year":"","journal-title":"J. Affect Disord."},{"key":"B185","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12916-015-0328-1","article-title":"No evidence that frailty modifies the positive impact of antihypertensive treatment in very elderly people: an investigation of the impact of frailty upon treatment effect in the HYpertension in the Very Elderly Trial (HYVET) study, a double-blind, placebo-controlled study of antihypertensives in people with hypertension aged 80 and over","volume":"13","author":"Warwick","year":"2015","journal-title":"BMC Med."},{"key":"B186","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14740338.2024.2387315","article-title":"Post-marketing safety surveillance of fostamatinib: an observational, pharmacovigilance study leveraging FAERS database","author":"Wei","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"key":"B187","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1038\/ki.2012.267","article-title":"Angiotensin II receptors mediate increased distal nephron acidification caused by acid retention","volume":"82","author":"Wesson","year":"2012","journal-title":"Kidney Int."},{"key":"B188","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S1474-4422(22)00169-7","article-title":"Diagnosis and treatment of orthostatic hypotension","volume":"21","author":"Wieling","year":"2022","journal-title":"Lancet Neurol."},{"key":"B189","doi-asserted-by":"publisher","first-page":"288S","DOI":"10.1093\/ajh\/4.4.288s","article-title":"In vivo pharmacology of DuP 753","volume":"4","author":"Wong","year":"1991","journal-title":"Am. J. Hypertens."},{"key":"B190","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1080\/14740338.2023.2296966","article-title":"Safety of daratumumab in the real-world: a pharmacovigilance study based on FAERS database","volume":"23","author":"Wu","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"key":"B191","doi-asserted-by":"publisher","first-page":"1200254","DOI":"10.3389\/fphar.2023.1200254","article-title":"A real-world pharmacovigilance analysis of FDA adverse event reporting system database for upadacitinib","volume":"14","author":"Wu","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B192","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1097\/00004872-200110000-00021","article-title":"Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout","volume":"19","author":"W\u00fcrzner","year":"2001","journal-title":"J. Hypertens."},{"key":"B193","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/s0895-7061(98)00117-4","article-title":"Long-term follow-up of acute renal failure caused by angiotensin converting enzyme inhibitors","volume":"11","author":"Wynckel","year":"1998","journal-title":"Am. J. Hypertens."},{"key":"B194","doi-asserted-by":"publisher","first-page":"749","DOI":"10.2169\/internalmedicine.53.1738","article-title":"Combination therapy of angiotensin II receptor blocker and thiazide produces severe hyponatremia in elderly hypertensive subjects","volume":"53","author":"Yamada","year":"2014","journal-title":"Intern Med."},{"key":"B195","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1254\/jphs.12283fp","article-title":"Angiotensin AT(1)-receptor blockers enhance cardiac responses to parasympathetic nerve stimulation via presynaptic AT(1) receptors in pithed rats","volume":"122","author":"Yamaki","year":"2013","journal-title":"J. Pharmacol. Sci."},{"key":"B196","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1159\/000524806","article-title":"Comprehensive analysis of ixazomib-induced adverse events using the Japanese pharmacovigilance database","volume":"100","author":"Yamaoka","year":"2022","journal-title":"Oncology"},{"key":"B197","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/ajh.2011.71","article-title":"Postmenopausal hypertension","volume":"24","author":"Yanes","year":"2011","journal-title":"Am. J. Hypertens."},{"key":"B198","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.2147\/IJN.S230949","article-title":"La2O3 nanoparticles induce reproductive toxicity mediated by the nrf-2\/ARE signaling pathway in kunming mice","volume":"15","author":"Yuan","year":"2020","journal-title":"Int. J. Nanomedicine"},{"key":"B199","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1056\/NEJMoa1008816","article-title":"Irbesartan in patients with atrial fibrillation","volume":"364","author":"Yusuf","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B200","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"B201","doi-asserted-by":"publisher","first-page":"e49846","DOI":"10.7759\/cureus.49846","article-title":"Marked hepatotoxicity associated with losartan treatment: a case report","volume":"15","author":"Zahedi","year":"2023","journal-title":"Cureus"},{"key":"B202","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14740338.2024.2393276","article-title":"Safety profiles of tetracycline-class drugs: a pharmacovigilance analysis of the FAERS database","author":"Zhang","year":"","journal-title":"Expert Opin. Drug Saf."},{"key":"B203","doi-asserted-by":"publisher","first-page":"1194545","DOI":"10.3389\/fphar.2023.1194545","article-title":"Safety analysis of pemigatinib leveraging the US Food and Drug administration adverse event reporting system","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B204","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14740338.2024.2393268","article-title":"Adverse events associated with Atogepant: a FAERS-based pharmacovigilance analysis","author":"Zhang","year":"","journal-title":"Expert Opin. Drug Saf."},{"key":"B206","doi-asserted-by":"publisher","first-page":"106789","DOI":"10.1016\/j.intimp.2020.106789","article-title":"Irbesartan may relieve renal injury by suppressing Th22 cells chemotaxis and infiltration in Ang II-induced hypertension","volume":"87","author":"Zhong","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"B207","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/s41569-021-00559-8","article-title":"Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension","volume":"18","author":"Zhou","year":"2021","journal-title":"Nat. Rev. Cardiol."},{"key":"B208","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14740338.2024.2393269","article-title":"A real-world disproportionality analysis of baloxavir marboxil: post-marketing pharmacovigilance data","author":"Zhou","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"key":"B209","doi-asserted-by":"publisher","first-page":"1320458","DOI":"10.3389\/fphar.2023.1320458","article-title":"A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database","volume":"14","author":"Zou","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B210","doi-asserted-by":"publisher","first-page":"1392914","DOI":"10.3389\/fphar.2024.1392914","article-title":"A disproportionality analysis of adverse events caused by GnRHas from the FAERS and JADER databases","volume":"15","author":"Zou","year":"2024","journal-title":"Front. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1485190\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T04:34:04Z","timestamp":1732077244000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1485190\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,20]]},"references-count":203,"alternative-id":["10.3389\/fphar.2024.1485190"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1485190","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,20]]},"article-number":"1485190"}}